drugset
Drugs / Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
last change Apr 2022 re-read 3 minutes ago

Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Cell therapy targets CD19

Developed for
B-cell acute lymphoblastic leukemia · B-cell chronic lymphocytic leukemia · diffuse large B-cell lymphoma · follicular lymphoma · lymphoplasmacytic lymphoma · mantle cell lymphoma · marginal zone lymphoma · Richter transformation
Investigated by
Allegheny Health Network · John Lister · Lentigen Technology, Inc. · Miltenyi Biotec, Inc.

Trials 1

today NCT05281809 · Ph 2
20222023202420252026202720282029203020312032203320342035203620372038
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05281809 Apr 2022 → Aug 2037 expected B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, Richter transformation, diffuse large B-cell lymphoma +4 John Lister Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) ClinicalTrials.gov intervention name — accepted as the source's own label NCT05281809 ↗
Modality Cell therapy “CAR T-cells targeting the CD19 antigen” NCT05281809 ↗
Route Intravenous “infused intravenously to the patient” NCT05281809 ↗
Target CD19 “CAR T-cells targeting the CD19 antigen” NCT05281809 ↗